A
ASOcura
Antisense oligonucleotide drugs for rare neurodegenerative diseases
About ASOcura
ASOcura is a biopharmaceutical company specializing in the development of antisense oligonucleotide (ASO) drugs. Founded in 2017 by Yimin Hua, the principal inventor of Nusinersen, the company is headquartered in Suzhou, China.
The company's core focus is on creating therapies for rare, neurodegenerative diseases by targeting RNA splicing and RNA editing. Its drug development pipeline targets conditions such as Duchenne muscular dystrophy (DMD), spinocerebellar ataxia type 3 (SCA3), and Huntington's disease, aiming to provide effective treatments for patients with these spinal degenerative diseases.
ASOcura has secured significant funding to advance its research and clinical trials. In July 2023, it closed a pre-series A+ funding round with Herui Venture Capital. This was followed by a Series A funding round in July 2024, raising CNY 100 million from investors including SDIC Venture Capital. The company plans to use this capital to accelerate product development and apply for clinical trial registrations.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- China
- Open positions
- None listed
- Dealroom signal
- 14.7/100
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jul 2024 | $14M | $55M | Herui Venture Capital · SDIC Venture Capital | ↗ |
Growth signals
Latest recorded traffic for ASOcura is 300 monthly website visits.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
ASOcura in its local ecosystem
The ASOcura office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
SDIC Venture Capital- HCHerui Venture Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about ASOcura on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ASOcura’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.